Results 51 to 60 of about 49,721 (234)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports

Case Reports in Oncology, 2020
A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy.
Tomoyuki Araya, Toshiyuki Kita, Hiroki Matsuoka, Tamami Sakai, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +1 more source

Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy

Neoplasia: An International Journal for Oncology Research, 2008
Nab-paclitaxel is an albumin-bound 130-nm particle form of paclitaxel that has shown an improved efficacy in experimental tumor models and clinical studies compared with solvent-based paclitaxel.
Lisa D. Volk, Michael J. Flister, Christopher M. Bivens, Alan Stutzman, Neil Desai, Vuong Trieu, Sophia Ran   +6 more
doaj   +1 more source

Pankreaskarzinom: Langzeitdaten zu nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
Nab-Paclitaxel konnte in einer grosen Phase-III-Studie das Gesamtuberleben von Patienten mit metastasiertem Pankreaskarzinom verlangern. Nun liegen Langzeitdaten dieser Studie vor.
openaire   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro­pathy: a cross-sectional cohort study

Acta Oncologica
Background and purpose: There remains limited evidence regarding the relative neurotoxic potential of nab-paclitaxel long-term. This cross-sectional matched cohort study aimed to compare the severity and natural history of chemotherapy-induced peripheral
Terry Trinh, Kimberley Au, Arun V. Krishnan, Hannah C. Timmins, Tiffany Li, Peter Grimison, David Goldstein, Susanna B. Park   +7 more
doaj   +1 more source

Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9‐CD36 Axis in Obesity‐Associated Pancreatic Adenocarcinoma

Advanced Science, EarlyView.
Pancreatic adenocarcinoma (PAAD) remains highly lethal with limited treatment options. This study demonstrates that coixenolide, a bioactive compound from Coix lacryma‐jobi L. and a key component of the clinically approved Kanglaite injection, exhibits enhanced antitumor efficacy in high‐fat diet (HFD)‐induced obese mice bearing PAAD tumors compared to
Kaidi Chen, Rong Chen, Wei Li, Bin Song, Ruiying Zhang, Lewei Dai, Yuwei Qi, Ruqian Chen, Yifan Xu, Hangbin Li, Jingyi Huang, Fangping Wu, Jianan Peng, Xinyu Wang, Yang Xiong, Chaofeng Mu, Guilin Cheng, Zhaoshen Li, Shanming Ruan, Lei Huang, Mancang Gu   +20 more
wiley   +1 more source

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel) [PDF]

Frontiers in Oncology, 2014
Platinum-based chemotherapy doublets have been the standard approach to first-line therapy for more than a decade. Many randomized trials testing new combinations have not been able to produce significant gains in patient outcomes when these studies have looked at an unselected patient population. The recognition of the biologic importance of histology
Blais, Normand, Hirsh, Vera
openaire   +3 more sources

Chemoproteomic Identification of AKT2 as a Paclitaxel‐Binding Protein via C─C Bond‐Linked Probe PTX‐4 in Paclitaxel‐Resistant Breast Cancer

Advanced Science, EarlyView.
ABSTRACT Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens. However, drug resistance in breast cancer limits therapeutic efficacy and contributes to recurrence and metastasis.
Kai Wang, Yuqing Yuan, Wei Shen, Xiuxiu Yang, Xiaokang Wu, Haihua Zhou, Yi Hu, Qing Zhu   +7 more
wiley   +1 more source

Nab-paclitaxel as second-line treatment in advanced biliary cancer.

, 2015
463 Background: Addition of nab-paclitaxel to gemcitabine has recently been demonstrated in the clinical phase III trial MPACT to be beneficial for progression free survival, overall response rate, and overall survival in advanced pancreatic cancer ...
Werner Scheithauer, Matthias Unseld, Gerald W. Prager, Christoph Zielinski, Gabriela Kornek, Guenther G. Steger   +5 more
core   +1 more source

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice [PDF]

, 2013
Design: Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (
Jodrell, D. I., Neesse, A., Tuveson, D. A., Frese, K. K., Chan, D. S., Richards, F. M., Bapiro, T. E., Ellenrieder, V., Howat, W. J.   +8 more
core   +2 more sources